Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cryo Cell International (CCEL) EBITDA Margin: 2010-2024

Historic EBITDA Margin for Cryo Cell International (CCEL) over the last 15 years, with FY2024 value amounting to 12.84%.

  • Cryo Cell International's EBITDA Margin rose 70600.0% to 24.29% in Q3 2025 from the same period last year, while for Aug 2025 it was 13.63%, marking a year-over-year increase of 531200.0%. This contributed to the annual value of 12.84% for FY2024, which is 510500.0% up from last year.
  • As of FY2024, Cryo Cell International's EBITDA Margin stood at 12.84%, which was up 510500.0% from 38.22% recorded in FY2023.
  • Cryo Cell International's EBITDA Margin's 5-year high stood at 25.58% during FY2020, with a 5-year trough of 38.22% in FY2023.
  • Moreover, its 5-year median value for EBITDA Margin was 14.36% (2022), whereas its average is 5.85%.
  • In the last 5 years, Cryo Cell International's EBITDA Margin crashed by -525800bps in 2023 and then surged by 510500bps in 2024.
  • Annual analysis of 5 years shows Cryo Cell International's EBITDA Margin stood at 25.58% in 2020, then tumbled by -43bps to 14.7% in 2021, then decreased by -2bps to 14.36% in 2022, then plummeted by -366bps to 38.22% in 2023, then skyrocketed by 134bps to 12.84% in 2024.
  • Its EBITDA Margin was 12.84% in FY2024, compared to 38.22% in FY2023 and 14.36% in FY2022.